Corient Private Wealth LP Takes Position in IQVIA Holdings Inc. $IQV

Key Points

• Corient Private Wealth initiated a 22,663-share IQVIA position valued at approximately $4.38 million. Institutional investors and hedge funds collectively own 89.62% of the company.
• Analyst sentiment remains positive, with one Strong Buy, thirteen Buy, and three Hold ratings; the consensus rating is Moderate Buy with a $241.88 price target.
• IQVIA exceeded quarterly expectations, reporting $3.15 in adjusted earnings per share and $4.37 billion in revenue, while revenue rose 8.7% year over year. The company also authorized a $2 billion share buyback covering up to 6.8% of outstanding shares.

Corient Private Wealth LP bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 22,663 shares of the medical research company's stock, valued at approximately $4,379,000.

Other institutional investors also recently made changes to their positions in the company. Korea Investment CORP purchased a new position in IQVIA in the 2nd quarter worth about $13,918,000. BlackRock Inc. acquired a new position in shares of IQVIA in the second quarter worth about $2,811,292,000. Deutsche Bank AG purchased a new position in shares of IQVIA in the second quarter worth approximately $143,074,000. Focus Partners Advisor Solutions LLC acquired a new stake in shares of IQVIA during the second quarter valued at approximately $976,000. Finally, Pallas Capital Advisors LLC acquired a new stake in shares of IQVIA during the second quarter valued at approximately $1,552,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IQV has been the subject of a number of research analyst reports. Mizuho increased their target price on IQVIA from $215.00 to $230.00 and gave the company an "outperform" rating in a report on Monday, July 13th. Robert W. Baird upped their price target on IQVIA from $252.00 to $287.00 and gave the company an "outperform" rating in a research report on Wednesday, July 29th. Morgan Stanley restated an "equal weight" rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. JPMorgan Chase & Co. lifted their target price on IQVIA from $225.00 to $285.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Finally, William Blair raised shares of IQVIA to a "strong-buy" rating in a research note on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $241.88.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the transaction, the insider owned 20,999 shares in the company, valued at $5,232,110.84. This trade represents a 19.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the transaction, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. This represents a 57.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 12,913 shares of company stock worth $3,098,793 over the last ninety days. Company insiders own 1.70% of the company's stock.

IQVIA Trading Down 0.2%

Shares of NYSE:IQV opened at $261.29 on Tuesday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $43.01 billion, a PE ratio of 32.42, a P/E/G ratio of 2.24 and a beta of 1.18. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $265.25. The firm has a fifty day moving average price of $224.00 and a 200 day moving average price of $190.15.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts' consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analysts' expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business's quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its board has initiated a share buyback plan on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.

About IQVIA

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.